GlassScriptPhysician profile
Steven Shamosh
NPI 1265639116
$10,841.31
in general payments reported to CMS, 2019-2025
28 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $407 · 2021: $1,040 · 2022: $1,235 · 2023: $3,009 · 2024: $3,571 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,951.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,544.57 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,466.08 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,325.90 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $1,111.21 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Janssen Pharmaceuticals, INC | $1,028.00 | 2019-2022 | |
| Pfizer INC. | $441.84 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $315.36 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $227.87 | 2023-2024 | Zepbound, Mounjaro |
| Astellas Pharma US INC | $179.76 | 2019-2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $163.66 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $142.88 | 2023-2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $135.61 | 2021 | |
| Novartis Pharmaceuticals Corporation | $106.34 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $98.82 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.44 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $72.54 | 2023-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.47 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $60.43 | 2022 | |
| Sun Pharmaceutical Industries INC. | $58.92 | 2021 | |
| Exact Sciences Corporation | $36.77 | 2023-2024 | Cologuard Collection Kit |
| Rgh Enterprises LLC | $29.38 | 2024 | |
| Amarin Pharma, INC. | $24.45 | 2020-2021 | |
| Tactile Systems Technology INC | $23.28 | 2023 | Entre Plus, Flexitouch Plus |
| Abbott Laboratories | $20.32 | 2024 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $18.34 | 2024 | Injectafer |
| Amgen INC. | $17.18 | 2022 | |
| Gilead Sciences, INC. | $15.27 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Shamosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.